Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 3
2016 5
2017 17
2018 21
2019 26
2020 16
2021 19
2022 16
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 33741648

101 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II, Open-label study to assess safety and management change using 68Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study.
Afaq A, Payne H, Davda R, Hines J, Cook GJR, Meagher M, Priftakis D, Warbey VS, Kelkar A, Orczyk C, Mitra A, Needleman S, Ferris M, Mullen G, Bomanji J. Afaq A, et al. J Nucl Med. 2021 Mar 19;62(12):1727-34. doi: 10.2967/jnumed.120.257527. Online ahead of print. J Nucl Med. 2021. PMID: 33741648 Free PMC article.
The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer.
Kulkarni M, Hughes S, Mallia A, Gibson V, Young J, Aggarwal A, Morris S, Challacombe B, Popert R, Brown C, Cathcart P, Dasgupta P, Warbey VS, Cook GJR. Kulkarni M, et al. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):674-686. doi: 10.1007/s00259-019-04643-7. Epub 2019 Dec 23. Eur J Nucl Med Mol Imaging. 2020. PMID: 31872280 Free PMC article.
68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. Calais J, et al. J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9. J Nucl Med. 2018. PMID: 29123013 Free PMC article.
PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.
Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, Hueper K, von Klot CA, Henkenberens C, Christiansen H, Thackeray JT, Ross TL, Bengel FM. Derlin T, et al. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):913-922. doi: 10.1007/s00259-017-3924-9. Epub 2018 Jan 7. Eur J Nucl Med Mol Imaging. 2018. PMID: 29308527
68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy.
Deandreis D, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, Nicolotti DG, Pilati E, Passera R, Zitella A, Bellò M, Parise R, Carlevato R, Ricardi U, Gontero P. Deandreis D, et al. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2804-2815. doi: 10.1007/s00259-020-04809-8. Epub 2020 Apr 20. Eur J Nucl Med Mol Imaging. 2020. PMID: 32314028
101 results